Any current/future capex/capital investment/strategic investment?

Completed around INR177 crores capex in FY '25. Planning INR150-200 crores capex in FY '26, including registration of oncology products and probable formulation production line expansion. Similar capex amount expected in FY '27 for new products. Saykha and Tarapur Greenfield projects underway, each ranging INR180-200 crores for Phase 1. Saykha plant capex approx. INR200 crores (50% captive consumption), Tarapur plant potential sales INR250-300 crores annually. Antidiabetic expansion line (~INR100 crores) deferred and may be taken up in a couple of years. Investment of INR8.05 crores committed

Future growth expectations in sales/revenue/volumes?

The company targets double-digit volume growth for FY '26, mainly driven by volume expansion rather than price increases. Expected sales growth of 10% to 15% overall, with formulations targeting 20% to 25% revenue growth. Consolidated revenue CAGR expected to be double-digit over the next 2 years. Short-term target is to cross INR 3,000 crores revenue, aiming for INR 3,500 crores later, primarily from volume growth. Expansion at Saykha and Tarapur plants will support growth, with full ramp-up expected by Q2 FY '26. New product launches (antifungals like fluconazole, metformin, metronidazole) a

Future growth expectations in earnings/operating earnings/profits/EPS?

FY '26 Revenue Growth: Targeting double-digit growth, around 10-15% overall despite new products and expansions. Formulations expected to grow 20-25%. FY '27 Revenue Target: Aim to achieve INR 3,000 crores revenue, with a further goal of INR 3,500 crores thereafter, driven by volume growth without rate improvements. Margins: Consolidated EBITDA margin guidance is stable at 14-15%, with potential operating leverage benefits from volume growth and cost savings. Cost Savings: INR 10-15 crores power & fuel savings expected in FY '26, scaling to INR 25-30 crores in subsequent years due to renewable

Aarti Drugs LtdQ1 FY26

Aarti Drugs Ltd Q1 FY26 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹416P/E: 19.5Market Cap: ₹3.8K Cr

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

→The company targets double-digit volume growth for FY '26, mainly driven by volume expansion rather than price increases.
→Expected sales growth of 10% to 15% overall, with formulations targeting 20% to 25% revenue growth.
→Consolidated revenue CAGR expected to be double-digit over the next 2 years.
→Short-term target is to cross INR 3,000 crores revenue, aiming for INR 3,500 crores later, primarily from volume growth.
→Expansion at Saykha and Tarapur plants will support growth, with full ramp-up expected by Q2 FY '26.
→New product launches (antifungals like fluconazole, metformin, metronidazole) and oncology formulations approvals planned in FY '26.
→Growth supported by increasing regulated market sales, backward integration, and higher capacity utilization.
→Contribution from both API and formulation segments to revenue growth.

Margin guidance

Category 3

→FY '26 Revenue Growth: Targeting double-digit growth, around 10-15% overall despite new products and expansions. Formulations expected to grow 20-25%.
→FY '27 Revenue Target: Aim to achieve INR 3,000 crores revenue, with a further goal of INR 3,500 crores thereafter, driven by volume growth without rate improvements.
→Margins: Consolidated EBITDA margin guidance is stable at 14-15%, with potential operating leverage benefits from volume growth and cost savings.
→Cost Savings: INR 10-15 crores power & fuel savings expected in FY '26, scaling to INR 25-30 crores in subsequent years due to renewable energy initiatives.
→Volume Growth Drivers: Major growth from antifungal fluconazole, metformin, and metronidazole volumes; specialty chemicals and backward integration to further improve margins.
→EPS/Profitability: PAT grew 33% YoY in Q4 FY '25, reflecting improving profitability, expected to continue with operational leverage and new capacities.

3 more insights locked — sign up free to unlock

Fundraise plans

- There is no explicit mention of any current or planned new fundraising through debt or equity in the provided transcript. - The company discusses significant ongoing and planned capital expenditure (capex), including: - INR177 crores invested in FY '25. - Planned capex of around INR150-200 crores in FY '26, with a similar amount expected in FY '27 for new products and expansions. - Deferred INR600 crores antidiabetic expansion capex to possibly start in a couple of years. - No direct reference to raising funds via equity or debt to finance these capex plans. - The company indicates operational improvements and margin expansion efforts, focusing on internal cash flows and cost savings (e.g., from renewable energy initiatives) rather than external fundraising. Hence, based on the transcript, no immediate or announced plans for fresh debt or equity fundraising.

Order book

The transcript does not explicitly mention the current or expected order book or pending orders for Aarti Drugs Limited. However, relevant insights can be inferred as follows: - Strong global demand for APIs was reported in Q4 FY '25, with volume growth around 15.5%, indicating healthy order flow. - New product launches and expanded capacity (e.g., antifungal fluconazole, metformin, metronidazole, salicylic acid, oncology and diabetic formulations) suggest a growing pipeline likely to contribute to future orders. - The company aims to maintain Q4 volumes as a base and grow sequentially with new plant ramp-ups and product introductions. - Clearance of the USFDA import alert is expected to improve regulated sales, particularly exports to North America and Europe, which may translate into an increased order backlog over 12–24 months. - Expansion projects at Saykha and Tarapur plants are expected to further support higher sales volumes. No specific quantitative data on order book or pending orders is disclosed.

Capex plans

Yes

→Completed around INR177 crores capex in FY '25.
→Planning INR150-200 crores capex in FY '26, including registration of oncology products and probable formulation production line expansion.
→Similar capex amount expected in FY '27 for new products.
→Saykha and Tarapur Greenfield projects underway, each ranging INR180-200 crores for Phase 1.
→Saykha plant capex approx. INR200 crores (50% captive consumption), Tarapur plant potential sales INR250-300 crores annually.
→Antidiabetic expansion line (~INR100 crores) deferred and may be taken up in a couple of years.
→Investment of INR8.05 crores committed in phased manner to acquire 26.25% equity in Prozeal Green Power Nine Pvt Ltd for 24.4 MW solar power plant supporting sustainability.
→Backward integration projects expected to reduce raw material dependence and improve margins long-term.

How does Aarti Drugs Ltd rank vs peers in ?

Pro feature

1Aarti Drugs Ltd

Rev 3Mar 3

See full sector rankings

Want more stocks like Aarti Drugs Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio